vs
Healthpeak Properties（DOC）与泰瑞达（TER）财务数据对比。点击上方公司名可切换其他公司
泰瑞达的季度营收约是Healthpeak Properties的1.5倍（$1.1B vs $719.4M），Healthpeak Properties净利率更高（73.2% vs 23.7%，领先49.4%），泰瑞达同比增速更快（43.9% vs 3.1%），Healthpeak Properties自由现金流更多（$357.0M vs $218.8M），过去两年泰瑞达的营收复合增速更高（34.4% vs 8.9%）
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
泰瑞达是总部位于美国马萨诸塞州北雷丁的自动测试设备（ATE）设计及制造企业，在全球半导体测试领域拥有深厚技术积累，服务的知名客户涵盖三星、高通、英特尔、亚德诺、德州仪器、IBM等行业头部企业。
DOC vs TER — 直观对比
营收规模更大
TER
是对方的1.5倍
$719.4M
营收增速更快
TER
高出40.8%
3.1%
净利率更高
DOC
高出49.4%
23.7%
自由现金流更多
DOC
多$138.3M
$218.8M
两年增速更快
TER
近两年复合增速
8.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $719.4M | $1.1B |
| 净利润 | $114.0M | $257.2M |
| 毛利率 | — | 57.2% |
| 营业利润率 | 17.4% | 27.1% |
| 净利率 | 73.2% | 23.7% |
| 营收同比 | 3.1% | 43.9% |
| 净利润同比 | 2406.4% | 75.9% |
| 每股收益（稀释后） | $0.16 | $1.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCTER
| Q4 25 | $719.4M | $1.1B | ||
| Q3 25 | $705.9M | $769.2M | ||
| Q2 25 | $694.3M | $651.8M | ||
| Q1 25 | $702.9M | $685.7M | ||
| Q4 24 | $698.0M | $752.9M | ||
| Q3 24 | $700.4M | $737.3M | ||
| Q2 24 | $695.5M | $729.9M | ||
| Q1 24 | $606.6M | $599.8M |
净利润DOCTER
| Q4 25 | $114.0M | $257.2M | ||
| Q3 25 | $-117.1M | $119.6M | ||
| Q2 25 | $31.7M | $78.4M | ||
| Q1 25 | $42.8M | $98.9M | ||
| Q4 24 | $4.5M | $146.3M | ||
| Q3 24 | $85.9M | $145.6M | ||
| Q2 24 | $146.0M | $186.3M | ||
| Q1 24 | $6.7M | $64.2M |
毛利率DOCTER
| Q4 25 | — | 57.2% | ||
| Q3 25 | 58.6% | 58.4% | ||
| Q2 25 | 60.2% | 57.2% | ||
| Q1 25 | 61.1% | 60.6% | ||
| Q4 24 | 60.3% | 59.4% | ||
| Q3 24 | 60.0% | 59.2% | ||
| Q2 24 | 60.6% | 58.3% | ||
| Q1 24 | 59.8% | 56.6% |
营业利润率DOCTER
| Q4 25 | 17.4% | 27.1% | ||
| Q3 25 | 9.2% | 18.9% | ||
| Q2 25 | 5.7% | 13.9% | ||
| Q1 25 | 7.7% | 17.6% | ||
| Q4 24 | -2.2% | 20.4% | ||
| Q3 24 | 14.1% | 20.6% | ||
| Q2 24 | 22.3% | 28.8% | ||
| Q1 24 | 3.7% | 13.0% |
净利率DOCTER
| Q4 25 | 73.2% | 23.7% | ||
| Q3 25 | -16.6% | 15.5% | ||
| Q2 25 | 4.6% | 12.0% | ||
| Q1 25 | 6.1% | 14.4% | ||
| Q4 24 | 0.7% | 19.4% | ||
| Q3 24 | 12.3% | 19.8% | ||
| Q2 24 | 21.0% | 25.5% | ||
| Q1 24 | 1.1% | 10.7% |
每股收益（稀释后）DOCTER
| Q4 25 | $0.16 | $1.62 | ||
| Q3 25 | $-0.17 | $0.75 | ||
| Q2 25 | $0.05 | $0.49 | ||
| Q1 25 | $0.06 | $0.61 | ||
| Q4 24 | $0.02 | $0.89 | ||
| Q3 24 | $0.12 | $0.89 | ||
| Q2 24 | $0.21 | $1.14 | ||
| Q1 24 | $0.01 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $467.5M | $293.8M |
| 总债务越低越好 | $9.8B | — |
| 股东权益账面价值 | $7.5B | $2.8B |
| 总资产 | $20.3B | $4.2B |
| 负债/权益比越低杠杆越低 | 1.31× | — |
8季度趋势，按日历期对齐
现金及短期投资DOCTER
| Q4 25 | $467.5M | $293.8M | ||
| Q3 25 | $91.0M | $272.7M | ||
| Q2 25 | $89.4M | $339.3M | ||
| Q1 25 | $70.6M | $475.6M | ||
| Q4 24 | $119.8M | $553.4M | ||
| Q3 24 | $180.4M | $510.0M | ||
| Q2 24 | $106.9M | $421.9M | ||
| Q1 24 | $101.8M | $707.4M |
总债务DOCTER
| Q4 25 | $9.8B | — | ||
| Q3 25 | $9.1B | — | ||
| Q2 25 | $9.0B | — | ||
| Q1 25 | $8.9B | — | ||
| Q4 24 | $8.7B | — | ||
| Q3 24 | $8.6B | — | ||
| Q2 24 | $8.6B | — | ||
| Q1 24 | $8.8B | — |
股东权益DOCTER
| Q4 25 | $7.5B | $2.8B | ||
| Q3 25 | $7.6B | $2.7B | ||
| Q2 25 | $7.9B | $2.8B | ||
| Q1 25 | $8.2B | $2.8B | ||
| Q4 24 | $8.4B | $2.8B | ||
| Q3 24 | $8.6B | $2.9B | ||
| Q2 24 | $8.8B | $2.7B | ||
| Q1 24 | $8.9B | $2.6B |
总资产DOCTER
| Q4 25 | $20.3B | $4.2B | ||
| Q3 25 | $19.6B | $4.0B | ||
| Q2 25 | $19.8B | $3.8B | ||
| Q1 25 | $19.8B | $3.7B | ||
| Q4 24 | $19.9B | $3.7B | ||
| Q3 24 | $20.0B | $3.8B | ||
| Q2 24 | $20.2B | $3.6B | ||
| Q1 24 | $20.5B | $3.4B |
负债/权益比DOCTER
| Q4 25 | 1.31× | — | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 1.04× | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.98× | — | ||
| Q1 24 | 0.99× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3B | $281.6M |
| 自由现金流经营现金流 - 资本支出 | $357.0M | $218.8M |
| 自由现金流率自由现金流/营收 | 49.6% | 20.2% |
| 资本支出强度资本支出/营收 | 124.4% | 5.8% |
| 现金转化率经营现金流/净利润 | 10.99× | 1.09× |
| 过去12个月自由现金流最近4个季度 | — | $450.4M |
8季度趋势，按日历期对齐
经营现金流DOCTER
| Q4 25 | $1.3B | $281.6M | ||
| Q3 25 | $315.0M | $49.0M | ||
| Q2 25 | $363.5M | $182.1M | ||
| Q1 25 | $279.4M | $161.6M | ||
| Q4 24 | $1.1B | $282.6M | ||
| Q3 24 | $318.2M | $166.3M | ||
| Q2 24 | $316.2M | $216.1M | ||
| Q1 24 | $152.6M | $7.3M |
自由现金流DOCTER
| Q4 25 | $357.0M | $218.8M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $131.7M | ||
| Q1 25 | — | $97.6M | ||
| Q4 24 | $333.7M | $225.2M | ||
| Q3 24 | — | $114.4M | ||
| Q2 24 | — | $171.2M | ||
| Q1 24 | — | $-36.7M |
自由现金流率DOCTER
| Q4 25 | 49.6% | 20.2% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 20.2% | ||
| Q1 25 | — | 14.2% | ||
| Q4 24 | 47.8% | 29.9% | ||
| Q3 24 | — | 15.5% | ||
| Q2 24 | — | 23.5% | ||
| Q1 24 | — | -6.1% |
资本支出强度DOCTER
| Q4 25 | 124.4% | 5.8% | ||
| Q3 25 | — | 6.1% | ||
| Q2 25 | — | 7.7% | ||
| Q1 25 | — | 9.3% | ||
| Q4 24 | 105.6% | 7.6% | ||
| Q3 24 | — | 7.0% | ||
| Q2 24 | — | 6.1% | ||
| Q1 24 | — | 7.3% |
现金转化率DOCTER
| Q4 25 | 10.99× | 1.09× | ||
| Q3 25 | — | 0.41× | ||
| Q2 25 | 11.48× | 2.32× | ||
| Q1 25 | 6.52× | 1.63× | ||
| Q4 24 | 235.43× | 1.93× | ||
| Q3 24 | 3.71× | 1.14× | ||
| Q2 24 | 2.17× | 1.16× | ||
| Q1 24 | 22.85× | 0.11× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOC
暂无分部数据
TER
| Soc | $646.5M | 60% |
| Memory | $206.5M | 19% |
| Transferred At Point In Time | $90.0M | 8% |
| Universal Robots | $89.4M | 8% |
| IST | $30.5M | 3% |
| Transferred Over Time | $20.5M | 2% |
